Immuno-Haematological Abnormalities of HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Therapy in the Antiretroviral Therapy Clinics of Six Health Facilities at Dessie Town, Northeast Ethiopia.
HAART
HIV
anemia
leukopenia
thrombocytopenia
Journal
Journal of blood medicine
ISSN: 1179-2736
Titre abrégé: J Blood Med
Pays: New Zealand
ID NLM: 101550884
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
03
2022
accepted:
05
05
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
In people living with the human immunodeficiency virus, haematological abnormalities have been linked to an increased risk of disease progression and mortality. Hematological parameters may have a positive or negative impact on antiretroviral therapy. The aim of this study was to assess the immuno-haematological abnormalities of HIV-infected patients before and after the initiation of highly active antiretroviral therapy in the antiretroviral therapy clinics of six health facilities in Dessie, Northeast Ethiopia. A facility-based cross-sectional study was conducted from April to May 30, 2021, at the antiretroviral therapy clinics of six health facilities in Dessie Town. A total of 378 HIV-infected patients taking highly active antiretroviral treatment for at least 6 months by using a consecutive sampling technique were included. A well-organized questionnaire was used to collect socio-demographic and clinical information. Immune-haematological parameters were tested using a Mindray BS-300 hematology analyzer and a BD FACS count CD4 analyzer. Statistical analysis was performed using SPSS version 25 statistical software. Statistical significance was defined as a P-value of 0.05 with a 95% confidence interval. Leukopenia was found in 26.7% and 16.5%, neutropenia in 16.5% and 9.4%, lymphopenia in 20% and 3.1%, and thrombocytopenia in 25.9% and 7.1% of HIV patients before and after HAART initiation, respectively. There was a significant difference in total white blood cell, absolute neutrophil, red blood cell, hemoglobin value, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, red cell distribution width, platelet and CD4+ T cell counts in HIV patients before and after the initiation of HAART with P < 0.05. Anemia, leukopenia, neutropenia, lymphopenia, and thrombocytopenia were the most common haematological abnormalities found in this study before and after HAART initiation. The prevalence of thrombocytopenia, immunosuppression, and viral load was reduced considerably after starting HAART.
Sections du résumé
Background
UNASSIGNED
In people living with the human immunodeficiency virus, haematological abnormalities have been linked to an increased risk of disease progression and mortality. Hematological parameters may have a positive or negative impact on antiretroviral therapy. The aim of this study was to assess the immuno-haematological abnormalities of HIV-infected patients before and after the initiation of highly active antiretroviral therapy in the antiretroviral therapy clinics of six health facilities in Dessie, Northeast Ethiopia.
Methods
UNASSIGNED
A facility-based cross-sectional study was conducted from April to May 30, 2021, at the antiretroviral therapy clinics of six health facilities in Dessie Town. A total of 378 HIV-infected patients taking highly active antiretroviral treatment for at least 6 months by using a consecutive sampling technique were included. A well-organized questionnaire was used to collect socio-demographic and clinical information. Immune-haematological parameters were tested using a Mindray BS-300 hematology analyzer and a BD FACS count CD4 analyzer. Statistical analysis was performed using SPSS version 25 statistical software. Statistical significance was defined as a P-value of 0.05 with a 95% confidence interval.
Results
UNASSIGNED
Leukopenia was found in 26.7% and 16.5%, neutropenia in 16.5% and 9.4%, lymphopenia in 20% and 3.1%, and thrombocytopenia in 25.9% and 7.1% of HIV patients before and after HAART initiation, respectively. There was a significant difference in total white blood cell, absolute neutrophil, red blood cell, hemoglobin value, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, red cell distribution width, platelet and CD4+ T cell counts in HIV patients before and after the initiation of HAART with P < 0.05.
Conclusion and Recommendation
UNASSIGNED
Anemia, leukopenia, neutropenia, lymphopenia, and thrombocytopenia were the most common haematological abnormalities found in this study before and after HAART initiation. The prevalence of thrombocytopenia, immunosuppression, and viral load was reduced considerably after starting HAART.
Identifiants
pubmed: 35592587
doi: 10.2147/JBM.S364700
pii: 364700
pmc: PMC9112337
doi:
Types de publication
Journal Article
Langues
eng
Pagination
243-253Informations de copyright
© 2022 Tilahun et al.
Déclaration de conflit d'intérêts
The authors state that they have no conflicts of interest in this research work.
Références
J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):383-92
pubmed: 15097155
J Blood Med. 2015 Apr 10;6:109-13
pubmed: 25926763
Int J Infect Dis. 2011 Dec;15(12):e808-11
pubmed: 21880530
Arch Iran Med. 2009 Mar;12(2):145-50
pubmed: 19249884
S Afr Med J. 2012 Mar 02;102(6):465-8
pubmed: 22668938
Int J Infect Dis. 2010 Dec;14(12):e1088-92
pubmed: 20961784
Indian J Hematol Blood Transfus. 2012 Jun;28(2):109-11
pubmed: 23730018
AIDS Res Ther. 2010 Dec 21;7:46
pubmed: 21176160
PLoS One. 2013 Aug 16;8(8):e72202
pubmed: 23977253
BMC Infect Dis. 2019 May 14;19(1):419
pubmed: 31088496
Infect Dis (Auckl). 2013 Mar 20;6:25-33
pubmed: 24847174
J Acquir Immune Defic Syndr. 2009 Dec;52(5):595-9
pubmed: 19734800
Biomed Res Int. 2020 Jan 28;2020:3132589
pubmed: 32090076
J Infect Dev Ctries. 2012 Sep 17;6(9):660-3
pubmed: 23000865
BMC Hematol. 2018 May 09;18:9
pubmed: 29760930
BMC Hematol. 2018 Apr 05;18:8
pubmed: 29632668
Nat Immunol. 2009 Sep;10(9):933-4
pubmed: 19692990
Blood Rev. 2002 Mar;16(1):73-6
pubmed: 11914001
PLoS One. 2020 Sep 15;15(9):e0239215
pubmed: 32931523
BMC Res Notes. 2014 Jan 06;7:5
pubmed: 24387326
BMC Hematol. 2014 Mar 25;14(1):8
pubmed: 24666771
Clin Infect Dis. 2007 Feb 1;44(3):441-6
pubmed: 17205456
BMC Infect Dis. 2014 Dec 21;14:3860
pubmed: 25528467
Anemia. 2014;2014:108593
pubmed: 24669317
Med J Islam Repub Iran. 2016 Apr 06;30:350
pubmed: 27390719
SAGE Open Med. 2021 May 28;9:20503121211020175
pubmed: 34104440
Afr Health Sci. 2011 Mar;11(1):2-15
pubmed: 21572851
AIDS. 2009 Jan 14;23(2):147-60
pubmed: 19098484
Front Immunol. 2017 May 23;8:580
pubmed: 28588579
Malawi Med J. 2017 Mar;29(1):43-52
pubmed: 28567196
BMC Res Notes. 2014 Oct 22;7:745
pubmed: 25335859
J Res Med Sci. 2012 Feb;17(2):138-42
pubmed: 23264786
Adv Hematol. 2019 Mar 03;2019:9614205
pubmed: 30941180
Int J Lab Hematol. 2020 Oct;42(5):565-572
pubmed: 32426940
HIV AIDS (Auckl). 2020 Jul 30;12:307-314
pubmed: 32801929
PLoS Pathog. 2008 Dec;4(12):e1000215
pubmed: 19112504
Int J Infect Dis. 2021 Apr;105:495-504
pubmed: 33684556
Blood. 2005 Jul 15;106(2):572-6
pubmed: 15774614
Mediators Inflamm. 2017;2017:6825493
pubmed: 29209103
Indian J Med Microbiol. 2008 Jul-Sep;26(3):256-8
pubmed: 18695327
JAMA. 1990 Sep 26;264(12):1556-9
pubmed: 2395196
S Afr Med J. 2019 Sep 10;109(8b):40-45
pubmed: 31662148
Antivir Ther. 2008;13(8):959-67
pubmed: 19195321